Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Herpes Zoster HELP
Based on 2,621 articles since 2006
||||

These are the 2621 published articles about Herpes Zoster that originated from Worldwide during 2006-2015.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline [Herpes Zoster and its prevention in Italy. Scientific consensus statement]. 2014

Franco, Elisabetta / Gabutti, Giovanni / Bonanni, Paolo / Conversano, Michele / Stefano Valente, Marco Ercolani / Ferro, Antonio / Icardi, Giancarlo / Antonio Volpi, Marzia Lazzari / Maggi, Stefania / Rossi, Alessandro / Scotti, Silvestro / Vitale, Francesco / Greco, Donato / Anonymous5440779. ·Università di Roma Tor Vergata. · Università di Ferrara. · Università di Firenze. · Presidente SItI, ASL di Taranto. · Sanofi Pasteur MSD. · ULSS17 del Veneto. · Università di Genova. · Direttivo SIGG. · Direttivo SIMG. · Direttivo FIMMG. · Università di Palermo, 12 Epidemiologo, Roma. · Epidemiologo, Roma. · ·Ig Sanita Pubbl · Pubmed #24770367.

ABSTRACT: In this paper, an Italian group of experts presents a revision of the available data about epidemiology and prevention of Herpes Zoster (HZ). HZ is an acute viral diseases caused by the reactivation of Varicella Zoster Virus (VZV). HZ is characterized by neurological and dermatological symptoms with a dermatomeric localization. The reactivation of the virus from the latent status in the sensitive ganglia increases with age and failing cell mediated immunity. In Europe, more than 95% of adults presents antibodies against VZV. Incidence of HZ is similar all over the world, related to the age of the population: from 2-3/1000 persons/year in the age group 20 to 50 years to 5/1000 in the 60 years old, 6-7/1000 between 70 and 80 up to >1/100 in older than 80. In Italy, about 157,000 new cases of HZ are estimated every year with an incidence of 6.3/1000 persons/year mostly in older adults. Among the hospitalized cases, 60% are over 65 years of age. The more frequent and severe complication of HZ is post herpetic neuralgia (PHN), characterized by severe localized pain lasting at least 3 month after the beginning of the acute phase. The pain is responsible for a sharp decrease in the quality of life. In Europe, PHN is described in 2.6-27% of HZ cases. In Italy, data obtained by a network of General Practitioner show PHN in 20.6% of HZ patients, while 9.2% of the patients still presents PHN at 6 months. The more frequent localization is thoracic; when the virus reactivate at the level of the ophthalmic division of the trigeminal nerve most patients develop ocular complications. The clinical and therapeutical managements of HZ patients is difficult and the results are often poor. Prevention of HZ e PHN in the population over 50 years is possible using a live attenuated vaccine containing VZV (Oka/Merck strain, not less than 19.400 plaque forming units), available since 2006. Efficacy of anti-HZ vaccine was demonstrated in two large clinical trials that showed a 51% reduction in the incidence of HZ and a 61% decrease of the burden of illness. Incidence of PHN showed a reduction of 67% in immunized subjects. Long-term follow-up showed a persistence of the protection even if a decrease was noted in older subjects and with time. Effectiveness studies confirm the data of clinical trials and numerous pharmaco-economical evaluation show a favorable profile of HZ vaccine. The vaccine is recommended in USA, Canada and some European countries for people over 60. The expert group concluded that HZ and PHN represent an important clinical and Public Health problem in Italy and that the possibility to prevent them should be carefully evaluated.

2 Guideline Vaccines for measles, mumps, rubella, varicella, and herpes zoster: immunization guidelines for adults. 2011

Hendriksz, Tami / Malouf, Philip / Foy, James E / Anonymous5290701. ·Division of Pediatrics, Touro University California, College of Osteopathic Medicine, Vallejo, CA 94592-1187, USA. tami.hendriksz@tu.edu · ·J Am Osteopath Assoc · Pubmed #22086887.

ABSTRACT: Although vaccinations are most commonly associated with the pediatric population, it is important for healthcare professionals to be familiar with the vaccines that are recommended for adults. The authors discuss 3 vaccines-the measles, mumps, and rubella (MMR) vaccine, the varicella vaccine, and the herpes zoster vaccine-including information about the diseases and complications that they protect against. Two doses, separated by 4 weeks, of both the MMR and varicella vaccines are recommended for all adults who do not have immunization or contraindications. All adults aged 60 years or older should receive a single dose of the herpes zoster vaccine unless they have contraindications. These 3 vaccines offer protection from illnesses that can have serious sequelae and substantial public health implications.

3 Guideline Update on herpes zoster vaccination: a family practitioner's guide. 2011

Shapiro, Marla / Kvern, Brent / Watson, Peter / Guenther, Lyn / McElhaney, Janet / McGeer, Allison. ·Department of Family and Community Medicine, University of Toronto, ON, Canada. MarlaMD@aol.com · ·Can Fam Physician · Pubmed #21998225.

ABSTRACT: OBJECTIVE: To answer frequently asked questions surrounding the use of the new herpes zoster (HZ) vaccine. SOURCES OF INFORMATION: Published results of clinical trials and other studies, recommendations from the Canadian National Advisory Committee on Immunization, and the US Advisory Committee on Immunization Practices; data were also obtained from the vaccine's Health Canada-approved product monograph. MAIN MESSAGE: Herpes zoster results from reactivation of the varicella-zoster virus; postherpetic neuralgia (PHN) is its most common and serious complication. The incidence of PHN after HZ is directly related to age, with 50% of affected individuals older than 60 years experiencing persistent and unrelieved pain. The live virus HZ vaccine reduces the incidence of HZ by about 50% and the occurrence of PHN by two-thirds, with vaccinated individuals experiencing attenuated or shortened symptoms. The vaccine is contraindicated in many immunocompromised patients and might not be effective in patients taking antiviral medications active against the HZ virus. Physicians should be aware of the different recommendations for these groups. CONCLUSION: The HZ vaccine is a safe and effective preventive measure for reducing the overall burden and severity of HZ in older adults. The vaccine appears to be cost-effective when administered to adults aged 60 years and older.

4 Guideline Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. 2009

Styczynski, J / Reusser, P / Einsele, H / de la Camara, R / Cordonnier, C / Ward, K N / Ljungman, P / Engelhard, D / Anonymous440635. ·Department of Pediatric Hematology and Oncology, Collegium Medicum UMK, Bydgoszcz, Poland. · ·Bone Marrow Transplant · Pubmed #19043458.

ABSTRACT: These guidelines on the management of HSV, VZV and EBV infection in patients with hematological malignancies and after SCT were prepared by the European Conference on Infections in Leukemia following a predefined methodology. A PubMed search was conducted using the appropriate key words to identify studies pertinent to management of HSV, VZV and EBV infections. References of relevant articles and abstracts from recent hematology and SCT scientific meetings were also reviewed. Prospective and retrospective studies identified from the data sources were evaluated, and all data deemed relevant were included in this analysis. The clinical and scientific background was described and discussed, and the quality of evidence and level of recommendation were graded according to the Centers for Disease Control criteria.

5 Guideline Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). 2008

Harpaz, Rafael / Ortega-Sanchez, Ismael R / Seward, Jane F / Anonymous3130610. ·Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, USA. · ·MMWR Recomm Rep · Pubmed #18528318.

ABSTRACT: These recommendations represent the first statement by the Advisory Committee on Immunization Practices (ACIP) on the use of a live attenuated vaccine for the prevention of herpes zoster (zoster) (i.e., shingles) and its sequelae, which was licensed by the U.S. Food and Drug Administration (FDA) on May 25, 2006. This report summarizes the epidemiology of zoster and its sequelae, describes the zoster vaccine, and provides recommendations for its use among adults aged > or =60 years in the United States. Zoster is a localized, generally painful cutaneous eruption that occurs most frequently among older adults and immunocompromised persons. It is caused by reactivation of latent varicella zoster virus (VZV) decades after initial VZV infection is established. Approximately one in three persons will develop zoster during their lifetime, resulting in an estimated 1 million episodes in the United States annually. A common complication of zoster is postherpetic neuralgia (PHN), a chronic, often debilitating pain condition that can last months or even years. The risk for PHN in patients with zoster is 10%-18%. Another complication of zoster is eye involvement, which occurs in 10%-25% of zoster episodes and can result in prolonged or permanent pain, facial scarring, and loss of vision. Approximately 3% of patients with zoster are hospitalized; many of these episodes involved persons with one or more immunocompromising conditions. Deaths attributable to zoster are uncommon among persons who are not immunocompromised. Prompt treatment with the oral antiviral agents acyclovir, valacyclovir, and famciclovir decreases the severity and duration of acute pain from zoster. Additional pain control can be achieved in certain patients by supplementing antiviral agents with corticosteroids and with analgesics. Established PHN can be managed in certain patients with analgesics, tricyclic antidepressants, and other agents. Licensed zoster vaccine is a lyophilized preparation of a live, attenuated strain of VZV, the same strain used in the varicella vaccines. However, its minimum potency is at least 14-times the potency of single-antigen varicella vaccine. In a large clinical trial, zoster vaccine was partially efficacious at preventing zoster. It also was partially efficacious at reducing the severity and duration of pain and at preventing PHN among those developing zoster. Zoster vaccine is recommended for all persons aged > or =60 years who have no contraindications, including persons who report a previous episode of zoster or who have chronic medical conditions. The vaccine should be offered at the patient's first clinical encounter with his or her health-care provider. It is administered as a single 0.65 mL dose subcutaneously in the deltoid region of the arm. A booster dose is not licensed for the vaccine. Zoster vaccination is not indicated to treat acute zoster, to prevent persons with acute zoster from developing PHN, or to treat ongoing PHN. Before administration of zoster vaccine, patients do not need to be asked about their history of varicella (chickenpox) or to have serologic testing conducted to determine varicella immunity.

6 Guideline Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). 2007

Marin, Mona / Güris, Dalya / Chaves, Sandra S / Schmid, Scott / Seward, Jane F / Anonymous3860587. ·Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, GA 30333, USA. mmarin@cdc.gov · ·MMWR Recomm Rep · Pubmed #17585291.

ABSTRACT: Two live, attenuated varicella zoster virus-containing vaccines are available in the United States for prevention of varicella: 1) a single-antigen varicella vaccine (VARIVAX, Merck & Co., Inc., Whitehouse Station, New Jersey), which was licensed in the United States in 1995 for use among healthy children aged > or = 12 months, adolescents, and adults; and 2) a combination measles, mumps, rubella, and varicella vaccine (ProQuad, Merck & Co., Inc., Whitehouse Station, New Jersey), which was licensed in the United States in 2005 for use among healthy children aged 12 months-12 years. Initial Advisory Committee on Immunization Practices (ACIP) recommendations for prevention of varicella issued in 1995 (CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 1996;45 [No. RR-11]) included routine vaccination of children aged 12-18 months, catch-up vaccination of susceptible children aged 19 months-12 years, and vaccination of susceptible persons who have close contact with persons at high risk for serious complications (e.g., health-care personnel and family contacts of immunocompromised persons). One dose of vaccine was recommended for children aged 12 months-12 years and 2 doses, 4-8 weeks apart, for persons aged > or = 13 years. In 1999, ACIP updated the recommendations (CDC. Prevention of varicella: updated recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 1999;48 [No. RR-6]) to include establishing child care and school entry requirements, use of the vaccine following exposure and for outbreak control, use of the vaccine for certain children infected with human immunodeficiency virus, and vaccination of adolescents and adults at high risk for exposure or transmission. In June 2005 and June 2006, ACIP adopted new recommendations regarding the use of live, attenuated varicella vaccines for prevention of varicella. This report revises, updates, and replaces the 1996 and 1999 ACIP statements for prevention of varicella. The new recommendations include 1) implementation of a routine 2-dose varicella vaccination program for children, with the first dose administered at age 12-15 months and the second dose at age 4-6 years; 2) a second dose catch-up varicella vaccination for children, adolescents, and adults who previously had received 1 dose; 3) routine vaccination of all healthy persons aged > or = 13 years without evidence of immunity; 4) prenatal assessment and postpartum vaccination; 5) expanding the use of the varicella vaccine for HIV-infected children with age-specific CD4+ T lymphocyte percentages of 15%-24% and adolescents and adults with CD4+ T lymphocyte counts > or = 200 cells/microL; and 6) establishing middle school, high school, and college entry vaccination requirements. ACIP also approved criteria for evidence of immunity to varicella.

7 Guideline Recommendations for the management of herpes zoster. 2007

Dworkin, Robert H / Johnson, Robert W / Breuer, Judith / Gnann, John W / Levin, Myron J / Backonja, Miroslav / Betts, Robert F / Gershon, Anne A / Haanpaa, Maija L / McKendrick, Michael W / Nurmikko, Turo J / Oaklander, Anne Louise / Oxman, Michael N / Pavan-Langston, Deborah / Petersen, Karin L / Rowbotham, Michael C / Schmader, Kenneth E / Stacey, Brett R / Tyring, Stephen K / van Wijck, Albert J M / Wallace, Mark S / Wassilew, Sawko W / Whitley, Richard J. ·Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, Rochester, NY, 14642, USA. robert_dworkin@urmc.rochester.edu. · ·Clin Infect Dis · Pubmed #17143845.

ABSTRACT: The objective of this article is to provide evidence-based recommendations for the management of patients with herpes zoster (HZ) that take into account clinical efficacy, adverse effects, impact on quality of life, and costs of treatment. Systematic literature reviews, published randomized clinical trials, existing guidelines, and the authors' clinical and research experience relevant to the management of patients with HZ were reviewed at a consensus meeting. The results of controlled trials and the clinical experience of the authors support the use of acyclovir, brivudin (where available), famciclovir, and valacyclovir as first-line antiviral therapy for the treatment of patients with HZ. Specific recommendations for the use of these medications are provided. In addition, suggestions are made for treatments that, when used in combination with antiviral therapy, may further reduce pain and other complications of HZ.

8 Editorial Physician advocacy for zoster vaccination. 2015

Kollipara, Ramya / Tyring, Stephen K. ·20320 Northwest Fwy, Ste 700, Houston, TX 77065, USA. rkollipara@ccstexas.com. · ·Cutis · Pubmed #26057503.

ABSTRACT: -- No abstract --

9 Editorial A new vaccine to prevent herpes zoster. 2015

Cohen, Jeffrey I. ·From the Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD. ·N Engl J Med · Pubmed #25916342.

ABSTRACT: -- No abstract --

10 Editorial Fingolimod and risk of varicella-zoster virus infection: back to the future with an old infection and a new drug. 2015

Tyler, Kenneth L. ·Department of Neurology, University of Colorado School of Medicine, Aurora. ·JAMA Neurol · Pubmed #25420159.

ABSTRACT: -- No abstract --

11 Editorial Editorial commentary: Waning efficacy of the herpes zoster vaccine. 2015

Whitley, Richard J. ·School of Medicine, University of Alabama at Birmingham. ·Clin Infect Dis · Pubmed #25416752.

ABSTRACT: -- No abstract --

12 Editorial Varicella vaccination in the immunocompromised. 2015

Malaiya, Ritu / Patel, Sanjeev / Snowden, Neil / Leventis, Pamela. ·Department of Rheumatology, St Helier Hospital, Carshalton, Surrey and Department of Rheumatology, North Manchester General Hospital, Manchester, UK. ritumalaiya@doctors.org.uk. · Department of Rheumatology, St Helier Hospital, Carshalton, Surrey and Department of Rheumatology, North Manchester General Hospital, Manchester, UK. ·Rheumatology (Oxford) · Pubmed #24758889.

ABSTRACT: -- No abstract --

13 Editorial Editorial commentary: zoster vaccine in immunocompromised patients: time to reconsider current recommendations. 2014

Oxman, Michael N / Schmader, Kenneth E. ·Infectious Diseases Section, Medicine Service, Veterans Affairs San Diego Healthcare System Division of Infectious Diseases, University of California San Diego School of Medicine. · Geriatric Research, Education and Clinical Center, Durham Veterans Affairs Medical Center Department of Medicine, Duke University, Durham, North Carolina. ·Clin Infect Dis · Pubmed #25097080.

ABSTRACT: -- No abstract --

14 Editorial Assessing correlates of protection in vaccine trials. 2014

Wittes, Janet. ·Statistics Collaborative, Washington, DC. ·J Infect Dis · Pubmed #24823622.

ABSTRACT: -- No abstract --

15 Editorial Editorial commentary: varicella zoster virus infection: generally benign in kids, bad in grown-ups. 2014

Nagel, Maria / Gilden, Don. ·Department of Neurology. · ·Clin Infect Dis · Pubmed #24700655.

ABSTRACT: -- No abstract --

16 Editorial Reassessing the link between herpes zoster ophthalmicus and stroke. 2014

Grose, Charles / Adams, Harold P. ·Division of Infectious Diseases/Virology, Children's Hospital, University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA. · ·Expert Rev Anti Infect Ther · Pubmed #24678919.

ABSTRACT: This editorial will assess a proposed link between herpes zoster ophthalmicus and subsequent stoke. Herpes zoster (also called shingles) is caused by varicella-zoster virus (VZV), one of the 9 human herpesviruses. When children contract their primary VZV infection, virus often travels to the trigeminal ganglia and establishes latency. Upon reactivation in late adulthood, the same virus travels anterograde to cause herpes zoster ophthalmicus. In some people, the virus also traffics from the same trigeminal ganglion along afferent fibers around the carotid artery and its branches. Subsequently VZV-induced inflammation within the affected cerebral arteries leads to occlusion and stroke. In one retrospective analysis of people with herpes zoster ophthalmicus, there was a 4.5 fold higher risk of stroke than in a control group. Two other studies found a less compelling association.

17 Editorial Immunisation for herpes zoster: current status. 2014

Cunningham, Anthony L / Litt, John C B / Macintyre, C Raina. ·Centre for Virus Research, Westmead Millennium Institute, Sydney, NSW, Australia. tony.cunningham@sydney.edu.au. · Department of General Practice, Flinders University, Adelaide, SA, Australia. · School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW, Australia. ·Med J Aust · Pubmed #24641130.

ABSTRACT: -- No abstract --

18 Editorial Herpes zoster ophthalmicus reduction: implementation of shingles vaccination in the UK. 2014

Potts, A / Williams, G J / Olson, J A / Pollock, K G J / Murdoch, H / Cameron, J C. ·Vaccine Preventable Diseases, Health Protection Scotland, NHS National Services Scotland, Meridian Court, Glasgow, UK. · Tennant Institute of Ophthalmology, Gartnavel General Hospital, Glasgow, UK. · The Eye Clinic, Aberdeen Royal Infirmary, Aberdeen, UK. ·Eye (Lond) · Pubmed #24622628.

ABSTRACT: -- No abstract --

19 Editorial Statins, immunomodulation, and infections: a complex and unresolved relationship. 2014

Pirmohamed, Munir. ·The Wolfson Centre for Personalised Medicine, Institute of Translational Medicine, University of Liverpool, United Kingdom. ·Clin Infect Dis · Pubmed #24253243.

ABSTRACT: -- No abstract --

20 Editorial Prevention of herpes zoster: we need to do better. 2013

Cohen, Elisabeth J. · ·JAMA Ophthalmol · Pubmed #23494045.

ABSTRACT: -- No abstract --

21 Editorial Functional anatomy of the facial nerve revealed by Ramsay Hunt syndrome. 2013

Gilden, Don. · ·Cleve Clin J Med · Pubmed #23376910.

ABSTRACT: -- No abstract --

22 Editorial It is an exciting time in the study and management of shingles and postherpetic neuralgia (PHN). Introduction. 2012

Yawn, Barbara P. · ·Popul Health Manag · Pubmed #23088663.

ABSTRACT: -- No abstract --

23 Editorial Development of CRPS after shingles: it's all about location. 2012

Oaklander, Anne Louise. · ·Pain · Pubmed #23059053.

ABSTRACT: -- No abstract --

24 Editorial Fingolimod and multiple sclerosis: four cautionary tales. 2012

Bourdette, Dennis / Gilden, Don. · ·Neurology · Pubmed #23035058.

ABSTRACT: -- No abstract --

25 Editorial Postherpetic neuralgia: the stealth attacker. 2012

Salcido, Richard Sal. · ·Adv Skin Wound Care · Pubmed #22610104.

ABSTRACT: -- No abstract --

Next